Application of cannabinoid compound to treatment of irritable bowel syndrome

A technology for irritable bowel syndrome and compounds, which can be applied to the active ingredients of hydroxyl compounds, medical preparations containing active ingredients, and the digestive system, etc. Progression rate, level reduction, effect of improving symptoms

Inactive Publication Date: 2018-11-23
HANYI BIO TECH CO LTD
View PDF4 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At the same time, contrary teachings have emerged in the prior art that

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cannabinoid compound to treatment of irritable bowel syndrome
  • Application of cannabinoid compound to treatment of irritable bowel syndrome
  • Application of cannabinoid compound to treatment of irritable bowel syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Example 1 Establishment of Chronic Stress-Induced Irritable Bowel Syndrome Rat Model

[0039] (1) Experimental principle:

[0040] The chronic unpredictability compound etiology method adopts a variety of stimulating factors, and the stimulating factors are arranged randomly, one stimulus per day, and each stimulus cannot appear continuously, so that the animal cannot predict the occurrence of the stimulus and can avoid the adaptation caused by a single stimulus. From the perspective of etiology, the environmental triggers of irritable bowel syndrome are simulated. After the evaluation of specificity and reliability, it is a classic chronic stress-induced irritable bowel syndrome model.

[0041] (2) Experimental group:

[0042] Control group 4 groups:

[0043] Blank control group, irritable bowel syndrome model group, pinaverium bromide positive control (10 mg / kg) group, itopride positive control (10 mg / kg) group.

[0044] Administration group 9 groups:

[0045] Giv...

Embodiment 2

[0057] Example 2 Effects of cannabinoids on the content of 5-HT in the duodenum of rats

[0058] (1) Experimental principle:

[0059] Elevated peripheral 5-hydroxytryptamine (5-HT) levels are an important pathogenesis of visceral hyperalgesia in IBS patients. In the previous study, the irritable bowel syndrome was effectively simulated by giving rats chronic stress. Using this model, the 5-HT content in the colon and serum of IBS rats was significantly increased, and the secretion level of gastrointestinal hormones was seriously affected. In the prior art, various drugs for treating IBS also judge the therapeutic effect by detecting the content of 5-HT in the colon and serum.

[0060] (2) Experimental group:

[0061] Rats were obtained according to the method described in Example 1, and were randomly divided into 13 groups, with 7 rats in each group.

[0062] Control group 4 groups:

[0063] Blank control group, irritable bowel syndrome model group, pinaverium bromide posi...

Embodiment 3

[0076] Example 3 Effects of cannabinoids on gastrointestinal motility in rats

[0077] (1) Experimental principle:

[0078] Irritable bowel syndrome is increasingly recognized as a disorder in which there is a "whole gastrointestinal" disorder, and small bowel motility disturbances have been found to be associated with multiple symptoms of IBS. The small intestine has a peristaltic function, and drugs that can promote intestinal peristalsis and inhibit intestinal peristalsis can change the peristaltic function of the small intestine. By observing the distance traveled by charcoal powder in the intestine, we can understand the influence of drugs on the peristaltic function of the small intestine.

[0079] (2) Experimental group:

[0080] Rats were also obtained according to the method described in Example 1, and were randomly divided into 13 groups with 7 rats in each group.

[0081] Control group 4 groups:

[0082] Blank control group, irritable bowel syndrome model group, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses use of one or more cannabinoid compounds or medicinal salts thereof to preparation of a pharmaceutical composition for treating irritable bowel syndrome. The invention furtherprovides a composition for treating irritable bowel syndrome. The composition comprises: 1) one or more cannabinoid compounds or medicinal salts thereof, and 2) one or more pharmaceutically acceptablecarriers or excipients.

Description

technical field [0001] The present invention relates to the application of a cannabinoid compound in the treatment of irritable bowel syndrome, in particular to the application of a composition containing one or more than two cannabinoid compounds in the treatment of irritable bowel syndrome. Background technique [0002] Irritable bowel syndrome (irritable bowel syndrome, IBS) is a common gastrointestinal disorder, characterized by abdominal pain or discomfort, accompanied by changes in stool properties and defecation habits. In the West, epidemiological surveys show that 10% to 20% of healthy people have suffered from this disease, and IBS patients account for more than 50% of the number of gastroenterology outpatients. However, it has been reported in the literature that the medical expenses consumed by IBS in the United States are about 800 million U.S. dollars per year. The incidence rate in Asian countries also reaches 5% to 10%. IBS has the characteristics of recurr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/352A61K31/05A61P1/00A61P1/12
CPCA61K31/05A61K31/352
Inventor 张可谭昕常坦然金倩
Owner HANYI BIO TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap